1. Criqui, MH, Matsushita, K, Aboyans, V, et al. Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association. Circulation. 2021;144(9):e171–e191.
Google Scholar | Crossref | Medline2. Nehler, MR, Duval, S, Diao, L, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. J Vasc Surg. 2014;60(3):686–695.e2.
Google Scholar | Crossref | Medline3. Virani, SS, Alonso, A, Benjamin, EJ, et al. Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596.
Google Scholar | Crossref | Medline4. Agarwal, S, Sud, K, Shishehbor, MH. Nationwide trends of hospital admission and outcomes among critical limb ischemia patients: from 2003-2011. J Am Coll Cardiol. 2016;67(16):1901–1913.
Google Scholar | Crossref | Medline5. Bonaca, MP, Nault, P, Giugliano, RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation. 2018;137(4):338–350.
Google Scholar | Crossref | Medline6. Bonaca, MP, Gutierrez, JA, Creager, MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2 degrees P-TIMI 50). Circulation. 2016;133(10):997–1005.
Google Scholar | Crossref | Medline | ISI7. Bonaca, MP, Scirica, BM, Creager, MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2P-TIMI 50. Circulation. 2013;127(14):1522–1529, 9e1–6.
Google Scholar | Crossref | Medline | ISI8. Gerhard-Herman, MD, Gornik, HL, Barrett, C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;69(11):e71–e126.
Google Scholar | Crossref | Medline9. Creager, MA, Kaufman, JA, Conte, MS. Clinical practice. Acute limb ischemia. N Engl J Med. 2012;366(23):2198–2206.
Google Scholar | Crossref | Medline | ISI10. Jones, WS, Baumgartner, I, Hiatt, WR, et al. Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease. Circulation. 2017;135(3):241–250.
Google Scholar | Crossref | Medline11. Conte, MS, Bradbury, AW, Kolh, P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019;58(1S):S1–S109.e33.
Google Scholar | Crossref | Medline12. Moxey, PW, Gogalniceanu, P, Hinchliffe, RJ, et al. Lower extremity amputations—a review of global variability in incidence. Diabet Med. 2011;28(10):1144–1153.
Google Scholar | Crossref | Medline | ISI13. Bonaca, MP, Bhatt, DL, Storey, RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67(23):2719–2728.
Google Scholar | Crossref | Medline14. Bonaca, MP, Creager, MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res. 2015;116(9):1579–1598.
Google Scholar | Crossref | Medline15. Hiatt, WR, Fowkes, FG, Heizer, G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376(1):32–40.
Google Scholar | Crossref | Medline | ISI16. Belch, JJ, Dormandy, J, Committee, CW, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52:825–833, 33 e1–2.
Google Scholar | Crossref | Medline | ISI17. Group DBS . Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (the Dutch bypass oral anticoagulants or aspirin study): a randomised trial. Lancet. 2000;355(9201):346–351.
Google Scholar | Crossref | Medline18. Warfarin Antiplatelet Vascular Evaluation Trial I , Anand, S, Yusuf, S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–227.
Google Scholar | Crossref | Medline | ISI19. Anand, SS, Bosch, J, Eikelboom, JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229.
Google Scholar | Crossref | Medline20. Bonaca, MP, Bauersachs, RM, Anand, SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004.
Google Scholar | Crossref | Medline21. Bonaca, MP, Morrow, DA. SCH 530348: a novel oral thrombin receptor antagonist. Future Cardiol. 2009;5(5):435–442.
Google Scholar | Crossref | Medline22. Weitz, JI, Angiolillo, DJ, Geisler, T, Heitmeier, S. Dual pathway inhibition for vascular protection in patients with atherosclerotic disease: rationale and review of the evidence. Thromb Haemost. 2020;120(8):1147–1158.
Google Scholar | Crossref | Medline23. Steg, PG, Bhatt, DL, Wilson, PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–1206.
Google Scholar | Crossref | Medline | ISI24. Weissler, EH, Jones, WS, Desormais, I, et al. Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy. Atherosclerosis. 2020;315:10–17.
Google Scholar | Crossref | Medline25. Magnani, G, Storey, RF, Steg, G, et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur Heart J. 2016;37(4):400–408.
Google Scholar | Medline26. Qamar, A, Morrow, DA, Creager, MA, et al. Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: analysis from the TRA 2°P-TIMI 50 trial. Vasc Med. 2020;25(2):124–132.
Google Scholar | SAGE Journals | ISI27. Pedersen, TR, Faergeman, O, Kastelein, JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437–2445.
Google Scholar | Crossref | Medline | ISI28. Olatidoye, AG, Wu, AHB, Feng, YJ, Waters, D. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol. 1998;81(12):1405–1410.
Google Scholar | Crossref | Medline29. Wang, TJ, Larson, MG, Levy, D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–663.
Google Scholar | Crossref | Medline | ISI